# Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

> **NCT06161545** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (estimated)

## Conditions studied

- Stage II Squamous Cell Carcinoma of the Head and Neck
- Stage III Squamous Cell Carcinoma of the Head and Neck
- Stage IV Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **BIOLOGICAL:** PD-L1 t-haNK cells
- **DRUG:** pembrolizumab
- **DRUG:** N-803

## Key facts

- **NCT ID:** NCT06161545
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-24
- **Primary completion:** 2026-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06161545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06161545, "Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06161545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*